ABSTRACT
Smart consumer devices with bioimpedance sensing technology apply an electrical current to the body for health and wellness. However, whether these smart devices interfere with cardiac implantable electronic devices (CIEDs) remains unknown. We report electrical interference with benchtop testing from the Galaxy Watch5 Pro and smart scale Body+ to cardiac resynchronization therapy device generators from different manufacturers. These results highlight the need of establishing standard testing procedures to assess the safety of smart devices with bioimpedance sensing in patients with CIEDs.
Competing Interest Statement
Dr. Sanchez is Co-Founder and holds equity in Haystack Diagnostics, Inc., the company has an option to license patented bioimpedance technology where the author is named an inventor. He holds equity and serves as Scientific Advisory Board Member of Ioniq Sciences, Inc., B-Secur, Ltd., and Physio AI, Inc. Dr. Sanchez consults for Myolex, Inc. and Impedimed, Inc., both companies have patented bioimpedance technology where the author is named an inventor. He serves as a consultant to Texas Instruments, Inc., Happy Health, Inc., Analog Devices, Inc., and Eko Health, Inc. Dr. Steinberg reports research support from AHA/PCORI, Abbott, Cardiva, Sanofi, and AltaThera; and consulting to Sanofi, InCarda, Milestone, Pfizer, and AltaThera. The other authors have no conflicts to declare. Dr. Freedman serves on the Cardiac Rhythm Management Medical Advisory Board for Abbott.
Funding Statement
Benjamin Sanchez was supported by an Institutional Research Grant, IRG-21-131-01 Grant DOI #: 10.53354/pc.gr.151058 from the American Cancer Society. He acknowledges the direct financial support for the research reported in this publication provided by the Huntsman Cancer Foundation and the Experimental Therapeutics Program at Huntsman Cancer Institute; the National Cancer Institute of the National Institutes of Health under Award Number P30CA042014 and R21CA273984; the National Science Foundation under Award Number 2319920. Benjamin A. Steinberg was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under Award Number K23HL143156. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest statement: Dr. Sanchez is Co-Founder and holds equity in Haystack Diagnostics, Inc., the company has an option to license patented bioimpedance technology where the author is named an inventor. He holds equity and serves as Scientific Advisory Board Member of Ioniq Sciences, Inc., B-Secur, Ltd., and Physio AI, Inc. Dr. Sanchez consults for Myolex, Inc. and Impedimed, Inc., both companies have patented bioimpedance technology where the author is named an inventor. He serves as a consultant to Texas Instruments, Inc., Happy Health, Inc., Analog Devices, Inc., and Eko Health, Inc. Dr. Steinberg reports research support from AHA/PCORI, Abbott, Cardiva, Sanofi, and AltaThera; and consulting to Sanofi, InCarda, Milestone, Pfizer, and AltaThera. The other authors have no conflicts to declare. Dr. Freedman serves on the Cardiac Rhythm Management Medical Advisory Board for Abbott.
Data Availability
NA
